GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006145831 | Oral cavity | NEOLP | reproductive system development | 91/2005 | 427/18723 | 8.18e-11 | 9.00e-09 | 91 |
GO:000641734 | Oral cavity | NEOLP | regulation of translation | 97/2005 | 468/18723 | 9.94e-11 | 1.05e-08 | 97 |
GO:004860831 | Oral cavity | NEOLP | reproductive structure development | 90/2005 | 424/18723 | 1.30e-10 | 1.33e-08 | 90 |
GO:200123632 | Oral cavity | NEOLP | regulation of extrinsic apoptotic signaling pathway | 44/2005 | 151/18723 | 3.30e-10 | 2.97e-08 | 44 |
GO:006219733 | Oral cavity | NEOLP | cellular response to chemical stress | 75/2005 | 337/18723 | 4.87e-10 | 3.97e-08 | 75 |
GO:000189031 | Oral cavity | NEOLP | placenta development | 42/2005 | 144/18723 | 8.01e-10 | 6.02e-08 | 42 |
GO:009719133 | Oral cavity | NEOLP | extrinsic apoptotic signaling pathway | 55/2005 | 219/18723 | 1.07e-09 | 7.82e-08 | 55 |
GO:004586133 | Oral cavity | NEOLP | negative regulation of proteolysis | 76/2005 | 351/18723 | 1.40e-09 | 9.80e-08 | 76 |
GO:005254833 | Oral cavity | NEOLP | regulation of endopeptidase activity | 88/2005 | 432/18723 | 1.82e-09 | 1.18e-07 | 88 |
GO:006101332 | Oral cavity | NEOLP | regulation of mRNA catabolic process | 45/2005 | 166/18723 | 2.67e-09 | 1.64e-07 | 45 |
GO:000640131 | Oral cavity | NEOLP | RNA catabolic process | 63/2005 | 278/18723 | 5.63e-09 | 3.07e-07 | 63 |
GO:000170132 | Oral cavity | NEOLP | in utero embryonic development | 76/2005 | 367/18723 | 1.11e-08 | 5.44e-07 | 76 |
GO:190331331 | Oral cavity | NEOLP | positive regulation of mRNA metabolic process | 35/2005 | 118/18723 | 1.25e-08 | 5.94e-07 | 35 |
GO:007259432 | Oral cavity | NEOLP | establishment of protein localization to organelle | 84/2005 | 422/18723 | 1.30e-08 | 6.10e-07 | 84 |
GO:000189231 | Oral cavity | NEOLP | embryonic placenta development | 27/2005 | 82/18723 | 5.12e-08 | 2.08e-06 | 27 |
GO:005134631 | Oral cavity | NEOLP | negative regulation of hydrolase activity | 75/2005 | 379/18723 | 9.98e-08 | 3.66e-06 | 75 |
GO:000756831 | Oral cavity | NEOLP | aging | 69/2005 | 339/18723 | 1.05e-07 | 3.83e-06 | 69 |
GO:003300221 | Oral cavity | NEOLP | muscle cell proliferation | 55/2005 | 248/18723 | 1.11e-07 | 4.03e-06 | 55 |
GO:001046632 | Oral cavity | NEOLP | negative regulation of peptidase activity | 57/2005 | 262/18723 | 1.32e-07 | 4.65e-06 | 57 |
GO:004348832 | Oral cavity | NEOLP | regulation of mRNA stability | 40/2005 | 158/18723 | 1.54e-07 | 5.28e-06 | 40 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C6 | SNV | Missense_Mutation | | c.201N>C | p.Lys67Asn | p.K67N | P13671 | protein_coding | tolerated(0.09) | possibly_damaging(0.717) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
C6 | SNV | Missense_Mutation | | c.1672G>A | p.Asp558Asn | p.D558N | P13671 | protein_coding | tolerated(0.09) | benign(0.29) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
C6 | SNV | Missense_Mutation | | c.1375N>G | p.Lys459Glu | p.K459E | P13671 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs369381506 | c.1067N>A | p.Arg356Gln | p.R356Q | P13671 | protein_coding | tolerated(0.17) | benign(0.098) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs763860114 | c.2522G>A | p.Arg841His | p.R841H | P13671 | protein_coding | tolerated(0.19) | benign(0.35) | TCGA-C8-A12Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | | c.311N>T | p.Arg104Ile | p.R104I | P13671 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
C6 | SNV | Missense_Mutation | novel | c.1177N>A | p.Glu393Lys | p.E393K | P13671 | protein_coding | tolerated(0.24) | benign(0.169) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828_829insG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | deletion | Frame_Shift_Del | rs372345940 | c.828delN | p.Ser277AlafsTer43 | p.S277Afs*43 | P13671 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828dupG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |